Sorafenib: advances in targeted therapy for renal cell carcinoma
Future Prescriber · 2006
DOI: 10.1002/fps.12 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Prescriber, 2006. Verfasst von Robert E Hawkins und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Sorafenib is the first dual action oral multi‐kinase inhibitor to target serine/threonine and receptor tyrosine kinases in both the tumour cell and the tumour vasculature. Phase II studies and now the largest ever phase III study in advanced renal cell cancer suggest that sorafenib will be a valuable new therapy for patients with kidney cancer. Copyright © 2006 John Wiley & Sons, Ltd.
Zitieren
APA
Hawkins, R. E., & Thistlethwaite, F. C. (2006). Sorafenib: advances in targeted therapy for renal cell carcinoma. Future Prescriber. https://doi.org/10.1002/fps.12
Vancouver
Hawkins RE, Thistlethwaite FC. Sorafenib: advances in targeted therapy for renal cell carcinoma. Future Prescriber. 2006. doi:10.1002/fps.12
BibTeX
@article{Hawkins2006,
author = {Hawkins, Robert E and Thistlethwaite, Fiona C},
title = {Sorafenib: advances in targeted therapy for renal cell carcinoma},
journal = {Future Prescriber},
year = {2006},
doi = {10.1002/fps.12}
}
EUVIMED